Your browser doesn't support javascript.
loading
Management of bone disease in patients undergoing hormonal therapy for breast cancer.
Mirza, Faryal Sardar Ali.
Afiliação
  • Mirza FS; Division of Endocrinology, University of Connecticut Health Center, Farmington, CT 06030, USA. fmirza@uchc.edu
Endocrinol Metab Clin North Am ; 40(3): 549-62, viii, 2011 Sep.
Article em En | MEDLINE | ID: mdl-21889720
Estrogen deficiency at menopause is associated with increased risk of bone loss and osteoporosis. Aromatase inhibitors (AIs) are increasingly being used for the treatment of postmenopausal hormone-sensitive breast cancer because of better disease-free survival compared with tamoxifen seen in clinical trials with AIs. This article reviews the effect of endocrine therapies of breast cancer on bone and the management of bone disease with these endocrine therapies. The effect of these therapies on bone mineral density and bone turnover along with possible interventions is discussed. AIs are also associated with skeletal-related events, which are not discussed.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas / Neoplasias da Mama / Carcinoma / Antineoplásicos Hormonais Tipo de estudo: Evaluation_studies Limite: Animals / Female / Humans Idioma: En Revista: Endocrinol Metab Clin North Am Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas / Neoplasias da Mama / Carcinoma / Antineoplásicos Hormonais Tipo de estudo: Evaluation_studies Limite: Animals / Female / Humans Idioma: En Revista: Endocrinol Metab Clin North Am Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2011 Tipo de documento: Article País de afiliação: Estados Unidos